Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Treatments in Endocrinology
- Vol. 4 (6) , 361-370
- https://doi.org/10.2165/00024677-200504060-00005
Abstract
The ‘incretin effect’ describes the phenomenon of an enhanced insulin response following oral ingestion of glucose compared with that after intravenous administration of glucose, leading to identical...Keywords
This publication has 67 references indexed in Scilit:
- Gastric Inhibitory Polypeptide: the neglected incretin revisitedRegulatory Peptides, 2002
- Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 DiabetesDiabetes, 2001
- No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP‐1 and intravenous glucoseDiabetic Medicine, 2001
- Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patientsDiabetologia, 1993
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993
- Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes MellitusNew England Journal of Medicine, 1992
- Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic SubjectsDiabetes Care, 1992
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANPublished by Elsevier ,1987
- Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*Journal of Clinical Endocrinology & Metabolism, 1986
- The incretin concept todayDiabetologia, 1979